• 목록
• 답변

Arbormed announced on the 6th that "ARBM-101," which is being developed as a treatment for Wilson's disease, has been selected as a research support project for the National New Drug Development Project Group (KDDF), the leader of the group, Muk Hyunsang.

The national new drug development project is a cross-ministerial national R&D project that supports the pre-stage of new drug development based on open innovation strategies of pharmaceutical companies, schools, research institutes, and hospitals to strengthen the global competitiveness of the domestic pharmaceutical and bio industry and secure pharmaceutical sovereignty.
With the support of the KDDF, Arbormed will finally verify the mechanical research, animal efficacy tests, and preliminary toxicity tests of ARBM-101.

Wilson's disease is a rare disease that occurs at a rate of one per 30,000 people worldwide, and it is known that there are about 1,500 patients in Korea and about 10,000 patients in the United States.
The size of the treatment market in the United States is estimated to be about 3 trillion won.

Arbormed said ARBM-101 is being developed for patients with severe liver disease with Wilson's disease. It was explained that related animal models have been found to have the effect of promoting the rapid discharge of copper from liver tissue while minimizing side effects.

Arbormed has announced the effects of ARBM-101 through several related journals and conferences, including the Gastroenterology (IF 33.883) and the American Association for the Study of Liver Disease (AASLD).